Table 2.

Clinical characteristics of patients.

	Overall patients (n = 92)	Control Group (n = 44)	Blood Ozonization Group (n = 48)	P
Age (years)	63.8 ± 13.2	64.2 ± 14.1	63.5 ± 12.5	0.784
Male	55 (59.8%)	24 (54.5%)	31 (64.6%)	0.443
BMI	27.0 ± 5.2	27.41 ± 6.02	26.6 ± 4.5	0.564
Charlson Comorbidity Index	2.0 [1.0–4.0]	3.0 [1.0–5.0]	2.0 [1.0–3.3]	0.444
Diabetes	15 (16.3%)	8 (18.2%)	7 (14.6%)	0.859
COPD	3 (3.3%)	3 (6.8%)	0 (0.0%)	0.218
Cronic heart disease	21 (22.8%)	9 (20.5%)	12 (26.1%)	0.702
Cronic renal failure	4 (4.4%)	3 (6.8%)	1 (2.1%)	0.563
Arterial hypertension	42 (45.7%)	19 (45.2%)	23 (47.9%)	0.966
Chronic home therapy
•ACE inibitors	14 (15.2%)	9 (20.5%)	5 (10.4%)	0.294
•Sartanics	15 (16.3%)	4 (9.1%)	11 (22.9%)	0.131
•Diuretics	18 (19.6%)	11 (25.0%)	7 (14.6%)	0.320
•Statins	11 (12.0%)	6 (13.6%)	5 (10.4%)	0.878
•Acetil salicilic acid	11 (12.0%)	5 (11.4%)	6 (12.5%)	1.000
•Other antiplatelet agents	3 (3.3%)	2 (4.6%)	1 (2.1%)	0.939
•Steroids	7 (7.6%)	3 (6.8%)	4 (8.3%)	1.000
•Proton pump inhibitors	17 (18.5%)	10 (22.7%)	7 (14.6%)	0.461
•Ormonal replacement therapy	5 (5.4%)	3 (6.8%)	2 (4.2%)	0.920
•Hydroxychloroquine	1 (1.1%)	1 (2.3%)	0 (0.0%)	0.965
Symptoms at COVID-19 onset
•Fever	80 (87.0%)	34 (77.3%)	46 (96.0%)	0.020
•Cough	46 (50.0%)	22 (50.0%)	24 (50.0%)	1.000
•Dyspnea	23 (25.0%)	16 (36.4%)	7 (14.6%)	0.030
•Myalgia	17 (18.5%)	9 (20.5%)	8 (16.7%)	0.843
•Sincope	3 (3.7%)	2 (4.6%)	1 (2.1%)	0.939
•Headache	8 (8.7%)	4 (9.1%)	4 (8.3%)	1.000
•Diarrhoea	25 (27.2%)	11 (25.0%)	14 (29.2%)	0.830
•Hypo/dysgeusia	8 (8.7%)	4 (9.1%)	4 (8.3%)	1.000
•Hypo/anosmia	8 (8.7%)	2 (4.6%)	6 (12.5%)	0.326
•Asthenia	9 (9.8%)	4 (9.1%)	5 (10.4%)	1.000

Legend: ACE - angiotensin-converting enzyme; BMI – body mass index; COPD - chronic obstructive pulmonary disease.